Treatment for High Urate
Start allopurinol as first-line therapy at a low dose (100 mg/day, or 50 mg/day if stage 4+ CKD), then titrate upward every 2-5 weeks to achieve serum urate <6 mg/dL (or <5 mg/dL if tophi present). 1, 2
When to Treat
Treat hyperuricemia only if the patient has gout (prior flares or tophi), not for asymptomatic hyperuricemia alone. 2, 3
- Do NOT treat asymptomatic hyperuricemia even with comorbid CKD, cardiovascular disease, or urolithiasis—randomized trials show no cardiovascular or renal benefit, and you would need to treat 24 patients for 3 years to prevent a single gout flare 2, 3
- Do treat if patient has had even one documented gout flare with hyperuricemia 1, 4
First-Line Pharmacologic Approach
Allopurinol (Preferred)
Allopurinol is the strongly recommended first-line agent for all patients, including those with moderate-to-severe CKD (stage ≥3). 1, 2
Dosing algorithm:
- Starting dose: 100 mg/day (or 50 mg/day if stage 4+ CKD) 5, 1, 2
- Titration: Increase by 100 mg every 2-5 weeks 5, 1
- Target: Serum urate <6 mg/dL (360 μmol/L) minimum; <5 mg/dL if tophi present 1, 5
- Maximum dose: Can exceed 300 mg/day even with renal impairment (up to 800 mg/day FDA-approved), with close monitoring for toxicity (rash, pruritus, elevated transaminases) 5, 2
Critical safety consideration: In high-risk populations (Koreans with stage 3+ CKD; Han Chinese and Thai patients regardless of renal function), consider HLA-B*5801 testing before starting allopurinol to reduce risk of severe hypersensitivity syndrome (20-25% mortality) 5
Alternative First-Line Options
If allopurinol is contraindicated or not tolerated:
- Febuxostat: Start 40 mg/day, titrate upward; strongly recommended over probenecid in CKD stage ≥3 1, 2
- Probenecid: First-choice uricosuric if XOI contraindicated, but NOT recommended if creatinine clearance <50 mL/min 5
Contraindications to uricosuric monotherapy:
- History of urolithiasis 5
- Elevated urinary uric acid (uric acid overproduction) 5
- Measure urinary uric acid before starting uricosurics 5
Refractory Disease Algorithm
If serum urate target not achieved with maximum-dose allopurinol:
- Switch XOI: Substitute febuxostat for allopurinol (or vice versa) if intolerance/adverse events 5
- Add uricosuric: Combine probenecid, fenofibrate, or losartan with XOI 5
- Pegloticase: Reserved for severe debilitating chronic tophaceous gout refractory to all other appropriately dosed therapies; NOT first-line 5, 1, 5
Monitoring Strategy
- During titration: Check serum urate every 2-5 weeks 1, 5
- Once at target: Monitor every 6 months to assess adherence 5
- On uricosurics: Continue monitoring urinary uric acid; consider urine alkalinization with potassium citrate (NOT sodium bicarbonate) if pH <6.0 5, 6
Flare Prophylaxis During ULT Initiation
Start prophylaxis when initiating urate-lowering therapy:
- Colchicine up to 1.2 mg/day (preferred) 1
- NSAIDs or low-dose glucocorticoids if colchicine contraindicated 1
- Duration depends on individual factors but continue until crystal dissolution 1
You can start ULT during an acute flare if effective anti-inflammatory therapy is instituted 5
Lifestyle Modifications (Adjunctive)
While pharmacologic therapy is primary, advise:
- Weight loss if appropriate 1
- Avoid beer, spirits, sugar-sweetened drinks, excessive meat/seafood 1
- Encourage low-fat dairy products 1
- Regular exercise 1
Common Pitfalls
- Underdosing allopurinol: Over 50% of patients fail to reach target on ≤300 mg/day—don't stop at 300 mg 5
- Treating asymptomatic hyperuricemia: No evidence of benefit; avoid unnecessary medication burden 2, 3
- Starting high-dose allopurinol: Increases hypersensitivity risk—always start low and titrate 5, 2
- Using probenecid in CKD: Ineffective when creatinine clearance <50 mL/min 5
budget:budget_used